At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
India is hosting the G20 summit. The leading theme of the G20 summit emphasizes health equity and sustainability as part of the agenda. How we provide access to healthcare for rural areas in India.
Boehringer Ingelheim acquires Global Stem cell Technology
Boehringer Ingelheim acquires Global Stem cell Technology, Belgian veterinary biotech company, to strengthen its stem cell capabilities in Animal Health
Our goal of transforming the treatment of neuroendocrine carcinomas
Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).
We drive innovation across our complex business landscape at Boehringer Ingelheim. Technology is an integral part of our core business processes and we focus on advanced technologies.